NetworkNewsBreaks Archive - Page 2207 of 2264

MondayFeb 27, 2017 12:10 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: HTGM 135.77% – News: Announces new direct-target sequencing chemistry available Q1 2017 OWCP 24.37% – News: Receives IRB approval for safety testing on topical cream to treat psoriasis MPAY 20.83% – News: Appoints new member to board of advisors OPCO 14.68% – News: Posts Q4 2016 results ATEA 14.56% – News: Completes independent audit LXRP 12.50% – News: Receives notice of patent to be accepted in Australia AXSM 8.14% – News: CEO presenting corporate…

MondayFeb 27, 2017 12:07 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Reports Positive Data from Phase I Trial of CLR 131 in Multiple Myeloma; Shares Higher

Cellectar Biosciences (NASDAQ: CLRB) this morning issued a positive update of its phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The data show that the 25 mCi/m2 dose was safe and well tolerated, and that adverse events were similar to those in the previous two cohorts. All four cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). While it is premature to report survival-related efficacy data from cohort 3, all patients in cohorts 1 and 2 continue to experience overall survival benefit. …

MondayFeb 27, 2017 12:04 pm

NetworkNewsBreaks – Pieris Pharmaceuticals (NASDAQ: PIRS) Grants ASKA Pharmaceutical Exclusive Option to License Anemia Drug in Japan

Pieris Pharmaceuticals (NASDAQ: PIRS) this morning announced that it has granted ASKA Pharmaceutical Co., Ltd. an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose phase 2a study in dialysis-dependent anemia patients. Per the agreement, Pieris will immediately receive an option payment of $2.75 million. Following an analysis period after the completion of the planned phase 2a study conducted by Pieris, ASKA may exercise its option to obtain an exclusive license to develop and commercialize PRS-080 in Japan, South Korea and certain other Asian…

MondayFeb 27, 2017 12:01 pm

NetworkNewsBreaks – OncoSec’s (NASDAQ: ONCS) ImmunoPulse® IL-12 Receives Fast Track Designation to Treat Metastatic Melanoma

OncoSec Medical (NASDAQ: ONCS) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic melanoma, following progression on pembrolizumab or nivolumab. The company this morning announced that this designation permits frequent communications and meetings with the FDA, providing opportunity for the upcoming phase 2b PISCES clinical trial of ImmunoPulse® IL-12 in combination with an intravenous anti-PD-1 antibody. The clinical trial is planned to initiate in the first half of 2017. "With the recent presentation of our interim…

MondayFeb 27, 2017 10:23 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) CEO Presents at Shandong Yibao Biologics Conference

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that CEO Warren Wang recently attended Shandong Yibao Biologics Co. Ltd.’s annual conference, where he was invited to deliver a speech celebrating Yibao Biologics’ 18th anniversary. A modern high-tech enterprise specializing in the research, production and sale of health care products, Yibao Biologics hosts an annual direct sales conference to discuss the development and prospects of Chinese health products enterprises in the United States. “The market for direct selling of natural products in the United States has considerable depth, and varies from the Chinese market in many ways,” Wang stated…

MondayFeb 27, 2017 9:49 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Scheduled to Present at 29th Annual ROTH Capital Partners Conference

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for eXp Realty LLC, this morning announced that it has been invited to present at the 29th Annual ROTH Capital Partners Conference, which is set to take place from March 12-15, 2017, at the Ritz-Carlton, Laguna Niguel in Dana Point, California. The company’s management team is scheduled to present on Monday, March 13 at 8:00 AM Pacific Time. For those unable to attend, a webcast of the presentation will be made available at http://wsw.com/webcast/roth31/expi. In addition to its presentation, the EXPI team is expected to host one-on-one meetings with prospective investors throughout…

FridayFeb 24, 2017 11:28 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 24, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: RMGN 10.64% – News: Converts Visual Supply Chain pilot with initial rollout sales order for global manufacturer ORPN 4.39% – News: Posts Q4, FY 2016 financial results VPRB 4.08% – News: Launches the MINIMAX Key FOB Battery AEMD 3.82% – News: CEO releases note on Bill Gates’ recent statement on bioterrorism threat JVA 3.45% – News: Acquires Comfort Foods Inc. ITEK 3.23% – News: Presenting at the American Glaucoma Society 2017 Annual Meeting March…

FridayFeb 24, 2017 11:23 am

NetworkNewsBreaks – Function(x), Inc. (NASDAQ: FNCX) Prices $4.8M Common Stock Offering, Hits 52-Week Low

Function(x) (NASDAQ: FNCX) shares dropped to $1.02 this morning after the social publishing and interactive media platform priced its underwritten public offering of 4,571,428 shares of its common stock at a public price of $1.05 per share. Additionally, the company has allowed the underwriters a 45-day option to purchase up to an additional 685,714 shares of common stock to cover over-allotments, if necessary. Before deducting underwriting discounts, commissions and other estimated offering expenses, the gross proceeds are expected to be approximately $4,800,000. Subject to customary closing conditions, the offering is expected to close on March 1, 2017. To view the…

FridayFeb 24, 2017 11:17 am

NetworkNewsBreaks – Cempra, Inc. (NASDAQ: CEMP) – Phase 3 Study of Fusidic Acid Achieves Primary Endpoint; Shares Rise

Cempra (NASDAQ: CEMP) shares rose 38% following the company’s report of positive topline results from a phase 3 study of oral fusidic acid. The study, which took place in 716 patients with acute bacterial skin and skin structure infections, demonstrated that fusidic acid was well tolerated. Additionally, the study realized the primary endpoint, demonstrating non-inferiority (NI) (10% NI margin) of oral fusidic acid compared to oral linezolid for early clinical response in the intent to treat patient population. The company plans to submit the full data from this study for presentation at an upcoming scientific forum. “We are excited that…

FridayFeb 24, 2017 11:13 am

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Shares Higher on FDA Approval of Two Strengths of Generic Glucophage® XR

Intellipharmaceutics International (NASDAQ: IPCI) shares were up 27% this morning following news that it has received final approval for its abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths from the U.S. Food and Drug Administration (FDA). Metformin hydrochloride extended release is a generic equivalent for the matching strengths of the branded product Glucophage® XR, which is sold in the United States by Bristol-Myers Squibb and indicated for use in the management of type 2 diabetes. "FDA approval of our application for a generic version of Glucophage® XR provides further…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks